These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25076257)

  • 41. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
    Ciccarese C; Iacovelli R; Mosillo C; Tortora G
    Clin Genitourin Cancer; 2018 Oct; 16(5):e1069-e1071. PubMed ID: 30005936
    [No Abstract]   [Full Text] [Related]  

  • 43. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.
    Linehan WM; Srinivasan R
    Nat Rev Clin Oncol; 2013 Nov; 10(11):614-5. PubMed ID: 24129349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 46. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
    Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
    Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
    [No Abstract]   [Full Text] [Related]  

  • 47. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Atrial flutter probably related to pazopanib: A case report].
    Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
    Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
    [No Abstract]   [Full Text] [Related]  

  • 49. Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma.
    Behzadigohar R; Rosenthal MA; Tran B
    Can J Urol; 2015 Jun; 22(3):7824-6. PubMed ID: 26068633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
    Bonate PL; Suttle AB
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
    Iacovelli R; Alesini D; Palazzo A; Trenta P; Santoni M; De Marchis L; Cascinu S; Naso G; Cortesi E
    Cancer Treat Rev; 2014 Mar; 40(2):271-5. PubMed ID: 24070900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pazopanib trial data cannot support first-line use.
    Jeldres C; Sun M; Perrotte P; Karakiewicz PI
    Nat Rev Urol; 2010 Jun; 7(6):307-8. PubMed ID: 20535144
    [No Abstract]   [Full Text] [Related]  

  • 55. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
    Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
    J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.
    Santoni M; Piva F; De Giorgi U; Mosca A; Basso U; Santini D; Buti S; Lolli C; Terrone C; Maruzzo M; Iuliani M; Bersanelli M; Conti A; Mazzucchelli R; Montironi R; Burattini L; Berardi R
    Anticancer Res; 2018 Oct; 38(10):5773-5782. PubMed ID: 30275199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
    Schmidinger M; Wittes J
    Curr Opin Urol; 2015 Sep; 25(5):395-401. PubMed ID: 26148069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Hess G; Borker R; Fonseca E
    Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
    Bourdeanu L; Twardowski P; Pal SK
    Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.